FierceBiotech

iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status

VANCOUVER, BRITISH COLUMBIA, Sep 29, 2010 (MARKETWIRE via COMTEX) -- iCo Therapeutics Inc. is pleased to announce that the Company's oral Amphotericin B program, "iCo-009", has been granted Orphan ...
UUHC Health Feed

ICO Host Designation: A Step Forward in Moran’s Fight to End Global Blindness

The International Council of Ophthalmology (ICO) has named the John A. Moran Eye Center as an official ICO Fellowship Host—a designation which brings both an honor and a boon to Moran’s work creating ...
FierceBiotech

iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus

iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 8, 2010) - ...